Big Pharma
13 September 2024 Sanofi will be responsible for global commercialisation of the medicine, used to treat neuroendocrine tumours | Pharma giant will pay up to $320m plus royalties to two biotech companies.
11 September 2024
5 September 2024
29 August 2024
Latest Features
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.
Europe
As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.
Big Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
Asia
Five cases in which preliminary injunctions were granted are examined by Takanori Abe of Abe & Partners.
Big Pharma
Life science attorneys should see some notable developments relating to artificial intelligence, patent eligibility and the Fintiv rule, write Manita Rawat and Alexander Stein of Morgan Lewis.
Asia
A Korean district court has applied a landmark ruling in a complicated vaccine dispute involving Pfizer, explain Young Kim, Yu-Seog WON, In Hwan Kim, and Amy Oh of Kim & Chang.
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills.
Americas
In part 2 of articles assessing the impact of 'Cellect v Samsung', Vincent Shier of Haynes Boone now sets out what the future may hold—both for this unusual case, as well as judicial doctrine in general.
More News
8 August 2024 A Delaware jury found AstraZeneca liable for induced infringement of a cancer treatment in May | Pharma company levelled allegations of "unclean hands" and "patent misuse" at Pfizer unit.
6 August 2024 Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.
1 August 2024 Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.
30 July 2024 Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise.
25 July 2024 The appointee represents a diverse range of tech clients, including in medtech and life sciences and will now lead the firm’s California offices.
23 July 2024 House of Representatives introduces bill to drive down cost of prescription drugs | Places “reasonable limit” on the number of patents a manufacturer can contest to prevent patent ‘thickets’ | Companion bill passed Senate earlier this month.
23 July 2024 Paris Central Division issues its first revocation judgment in dispute brought by Meril subsidiaries in Italy, Germany and India | Decision means infringement action by Edwards can resume at Munich Local Division | Damages worth €8m ($8.7m) | Gide, Marks & Clerk, Potter Clarkson among representatives.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox